These data highlight an efficient 2-in-1 combined KO/KI strategy that can be used to generate functionally enhanced ex vivo expanded NK cells that are optimized for CD38-directed ADCC against myeloma cells. The gene discussed is CD38; the disease is plasma cell myeloma.